

---

## **BRADFORD HEAD & NECK UPDATE**

Bradford Teaching Hospitals NHS Foundation Trust reported that all specialist Head & Neck cases are now being carried out in Bradford and therefore delivering an IOG compliant service.

## **SUPPORTIVE & PALLIATIVE CARE IMPROVING OUTCOMES GUIDANCE (IOG) IMPLEMENTATION UPDATE**

The Board received an outline of the complexities of delivering the Supportive & Palliative Care IOG and were informed of the recently agreed Department of Health monitoring framework and the risks for the Network associated with delivery (required by December 2009).

A gap analysis is in the process of being developed and the Board requested that it clarifies the work that needs to happen at National, Network and Local level. A particular risk area identified was the absence of a Network Allied Healthcare Professional (AHP) Lead. A bid for a 3-year AHP project post working across the YCN & HYCCN is being submitted to Macmillan for consideration in May.

The Board agreed that monitoring the implementation of the Guidance would be undertaken by the YCN Commissioning Group and the Locality Groups and that robust leadership and action plans with timescales for delivery should be in place.

## **CHILDREN & YOUNG PEOPLES IOG – FUNDING AGREEMENT PROCESS**

The Board supported the proposal that challenge to the funding associated with delivering the Principle Treatment Centres based at LTHT should be taken forward by NHS Leeds as consortium lead in partnership with SCG.

## **GOING FURTHER ON CANCER WAITS – LOCALITY ACTION PLANS UPDATE**

Locality Groups provided an updated on their action plans. Common challenges were around lung, urology, skin and colorectal. The Board recognised the importance of sharing good practice across the Network.

## **YCN WORK PROGRAMME 2009/10**

An outline Work Programme for the Network was presented for comment. The Board approved and supported the work programme subject to minor amendments.

## **CO-PAYMENT – CONSULTATION AND INTERIM NETWORK APPROACH**

The Board were presented with a paper which highlighted the issues that organisations need to consider as and when approached by patients wishing to purchase additional care. The aim being to deliver consistency in practice across the YCN.

The Board supported the approach with some amendments and additions and asked for a revised paper to be agreed, legal advice sought and the paper to be circulated as soon as possible.

## **AML 17 TRIAL**

The Board supported the national trial for patients with acute myeloid leukaemia (including patients with acute promyelocytic leukaemia) and high risk myelodysplastic syndrome.